Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes.[6] It is used by injection under the skin.[6] It is effective for up to 24 hours.[6]
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain.[6] Use in pregnancy and breastfeeding appears safe.[7] It works by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[6]
Insulin detemir was approved for medical use in the European Union in June 2004, and in the United States in June 2005.[5][6][8] It is on the World Health Organization's List of Essential Medicines.[9] In 2021, it was the 117th most commonly prescribed medication in the United States, with more than 5million prescriptions.[10][11]
^"Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
^"Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
^"Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
^"Levemir- insulin detemir injection, solution". DailyMed. 24 March 2020. Retrieved 19 October 2020.
^ ab"Levemir EPAR". European Medicines Agency (EMA). Retrieved 14 April 2020.
^ abcdef"Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
^"Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Retrieved 14 April 2020.
^"Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Retrieved 14 April 2020.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^"Insulin Detemir - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
Insulindetemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2...
long-acting insulins such as insulin glargine and insulindetemir), making it a once-daily basal insulin, that is one that provides a base insulin level, as...
marketed long-acting insulins such as insulin glargine and insulindetemir). Sanofi-Aventis developed glargine as a longer-lasting insulin analogue, and sells...
NPH insulin to other insulin analogues (insulindetemir, insulin glargine, insulin degludec) in both children and adults with Type 1 diabetes. Insulin detemir...
between insulin glargine and cancer. Previous studies had raised concerns. When comparing insulin glargine to NPH insulin, insulindetemir or insulin degludec...
long-acting insulin preparations. As a systematic review of studies comparing insulindetemir, insulin glargine, insulin degludec and NPH insulin did not...
Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is...
controlled). When nightly insulin is insufficient, twice daily insulin may achieve better control. The long acting insulins glargine and detemir are equally safe...
Insulin icodec, sold under the brand name Awiqli, is a medication used for the treatment of diabetes to improve glycemic control. It is an ultralong-acting...
being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be...
standard of basal insulin. Long-acting insulin analogs such as insulin glargine (brand name Lantus, made by Sanofi-Aventis) and insulindetemir (brand name...
in conjunction with insulin therapy.[citation needed] Mainly used in Type II diabetes, metformin is considered to increase insulin sensitivity in vivo...
fasting plasma glucose and HBA1c in diabetes patients. Saroglitazar is an insulin sensitizer. It is a first in class drug which acts as a dual PPAR agonist...
It works by decreasing glucose production in the liver, increasing the insulin sensitivity of body tissues, and increasing GDF15 secretion, which reduces...
to enhance growth of pancreatic beta cells, which are responsible for insulin production and release. Additionally, it inhibits the production of glucagon...
receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common...
diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately...
sulfonylurea family of medications. It works mostly by increasing the release of insulin. Gliclazide was patented in 1966 and approved for medical use in 1972....
resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs. Nateglinide is contraindicated...
increasing secretion of insulin from the beta cells in the pancreas. Sulfonylureas are ineffective where there is absolute deficiency of insulin production such...
calcium leads to increased fusion of insulin granula in the cell membrane, and therefore increased secretion of (pro) insulin. Blicklé JF (April 2006). "Meglitinide...
Lente insulin (from Italian lento, "slow"; also called insulin zinc suspension) was an intermediate duration insulin that is no longer used in humans....
sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. Glibenclamide was discovered in 1969 and approved for...
Ultralente insulin was a long-acting form of insulin. It has an onset of 4 to 6 hours, a peak of 14 to 24 hours, and a duration of 28 to 36 hours. Ultralente...
2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs...
Global Information
(what is this?) (verify)